Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer
- 29 December 2011
- journal article
- research article
- Published by Massachusetts Medical Society in The New England Journal of Medicine
- Vol. 365 (26), 2473-2483
- https://doi.org/10.1056/nejmoa1104390
Abstract
Vascular endothelial growth factor is a key promoter of angiogenesis and disease progression in epithelial ovarian cancer. Bevacizumab, a humanized anti–vascular endothelial growth factor monoclonal antibody, has shown single-agent activity in women with recurrent tumors. Thus, we aimed to evaluate the addition of bevacizumab to standard front-line therapy.Keywords
This publication has 27 references indexed in Scilit:
- 2010 Gynecologic Cancer InterGroup (GCIG) Consensus Statement on Clinical Trials in Ovarian Cancer: Report From the Fourth Ovarian Cancer Consensus ConferenceInternational Journal of Gynecologic Cancer, 2011
- Safety of Bevacizumab in Patients with Advanced Cancer: A Meta-Analysis of Randomized Controlled TrialsThe Oncologist, 2010
- Effects of Anti-VEGF Treatment Duration on Tumor Growth, Tumor Regrowth, and Treatment EfficacyClinical Cancer Research, 2010
- Vascular Endothelial Growth Factor Stimulates Organ-Specific Host Matrix Metalloproteinase-9 Expression and Ovarian Cancer InvasionMolecular Cancer Research, 2008
- Phase II Trial of Bevacizumab in Persistent or Recurrent Epithelial Ovarian Cancer or Primary Peritoneal Cancer: A Gynecologic Oncology Group StudyJournal of Clinical Oncology, 2007
- What is the risk of bowel perforation associated with bevacizumab therapy in ovarian cancer?Gynecologic Oncology, 2007
- The Relationship of Molecular Markers of p53 Function and Angiogenesis to Prognosis of Stage I Epithelial Ovarian CancerClinical Cancer Research, 2005
- Circulating plasma vascular endothelial growth factor in mice bearing human ovarian carcinoma xenograft correlates with tumor progression and response to therapyMolecular Cancer Therapeutics, 2005
- Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic TherapyScience, 2005
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI Journal of the National Cancer Institute, 2000